

Application/Control Number: 10/760,970

Page 2

Art Unit: 1623

CLMPTO

01/20/2004


DM

Claims 1-64 (Cancel)

Claims 65-77 (Original)



Art Unit: 1623

65. A pharmaceutical composition useful for the treatment of inflammatory disease or for reducing inflammation which composition comprises an inflammation reducing effective amount of a compound having the formula




wherein R_2 is hydrogen, a monomeric glycoside or an oligomeric glycoside, R_3 is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula $\text{—CH}(\text{CH}_3)\text{C}(=\text{O})\text{—OCH}_2\text{O—R}_8$, R is a lower alkylene, R' is

selected from the group consisting of moieties having the formula




and



Art Unit: 1623


where $X = 0$ or 1 , $Y = 0$ or 1 ,

R_1 is hydrogen or a pharmacologically active drug residue, R_8 a pharmacologically active drug residue, R_4 , R_5 , and R_6 are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




and R_7 is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

66. A pharmaceutical composition useful for the treatment of infectious disease or for reducing infection which composition comprises an infection reducing effective amount of a compound having the formula



wherein R_2 is hydrogen, a monomeric glycoside or an oligomeric glycoside, R_3 is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula $-\text{CH}(\text{CH}_3)\text{C}(=\text{O})\text{OCH}_2\text{O}-R_8$, R is a lower alkylene, R' is


selected from the group consisting of moieties having the formula



Art Unit: 1623


where $X = 0$ or 1 , $Y = 0$ or 1 ,

R_1 is hydrogen or a pharmacologically active drug residue, R_8 a pharmacologically active drug residue, R_4 , R_5 , and R_6 are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




and R_7 is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

67. A pharmaceutical composition useful for the treatment of glaucoma or for reducing intraocular pressure which composition comprises a therapeutically effective amount of a compound having the formula



wherein R_2 is hydrogen, a monomeric glycoside or an oligomeric glycoside, R_3 is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula $-\text{CH}(\text{CH}_3)\text{C}(=\text{O})\text{OCH}_2\text{O}-R_8$, R is a lower alkylene, R' is


selected from the group consisting of moieties having the formula



where $X = 0$ or 1 , $Y = 0$ or 1 .


Art Unit: 1623

R_1 is hydrogen or a pharmacologically active drug residue, R_8 a pharmacologically active drug residue, R_4 , R_5 , and R_6 are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




and R_7 is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

68.A pharmaceutical composition useful for administering therapeutic compositions ocularly for the treatment of systemic disorders, which composition comprises a therapeutically effective amount of a compound having the formula



wherein R_2 is hydrogen, a monomeric glycoside or an oligomeric glycoside, R_3 is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula $\text{---CH}(\text{CH}_3)\text{C}(=\text{O})\text{---OCH}_2\text{O---R}_8$, R is a lower alkylene, R' is


selected from the group consisting of moieties having the formula



Art Unit: 1623


where $X = 0$ or 1 , $Y = 0$ or 1 ,

R_1 is hydrogen or a pharmacologically active drug residue, R_8 a pharmacologically active drug residue, R_4 , R_5 , and R_6 are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




and R_7 is hydroxyl or hydroxyalkyl, with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

69. A compound having the formula




wherein R_2 and R_3 are independently hydrogen, or a glycoside having the formula




where $n=0$ to 8 and R_9 is an alkyl, alkylene, monocationic alkylamine or polycationic alkylamine.

Art Unit: 1623

R is a lower alkylene, R' is




where X = 0 or 1, Y = 0 or 1, R₁ is hydrogen or a pharmacologically active drug residue, and R₄, R₅, and R₆ are independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl or together form a nitrogen-containing ring selected from the group consisting of




with the proviso that said compound contains at least one pharmacologically active drug residue, or a pharmaceutically acceptable salt thereof.

70. The compound of Claim 69 wherein R₂ is hydrogen and R₃ is a glycoside having the formula



Art Unit: 1623

71. The compound of Claim 70 wherein R_3 is a glycoside having the formula




where $n=0$.

72. The compound of Claim 70 wherein R_9 is a monocationic alkylamine or polycationic alkylamine.


73. The compound of Claim 72 wherein the alkylamine is a quaternary amine.

74. The compound of Claim 71 having the formula



Art Unit: 1623

75. The compound of Claim 70 having the formula



76. The compound of Claim 75 wherein R_9 is a monocationic alkylamine or polycationic alkylamine.

77. The compound of Claim 76 wherein the alkylamine is a quaternary amine.